Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay Popat

Showing results (1-10 of 272) with videos related to

Pageof 28
Sort By:
The New England Journal of Medicine|January 11, 2018
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung CancerSanjay Popat
Annals of Palliative Medicine|April 6, 2015
Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?Sanjay Popat
Cancer|February 16, 2019
Hyperprogression with immunotherapy: Is it real?Sanjay Popat
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2019
Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's ClothingSanjay Popat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Do Statins Improve Survival in Small-Cell Lung Cancer?Sanjay Popat
Thorax|April 12, 2013
What exactly are we doing to improve low lung cancer survival in the United Kingdom?Eric Lim, Sanjay Popat
Journal of Pediatric Surgery|November 18, 2005
Urethral polyp in neonate: a rare occurrenceAmit Sitapara, Sanjay Popat
Drugs|June 9, 2021
Immune Checkpoint Inhibition for Unresectable Malignant Pleural MesotheliomaWanyuan Cui, Sanjay Popat
Lancet (London, England)|July 9, 2023
Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligibleHazel O'Sullivan, Sanjay Popat
Therapeutic Advances in Medical Oncology|March 28, 2017
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implicationsOscar Juan, Sanjay Popat
Pageof 28

Showing results (1-10 of 272) with videos related to

Sort By:
Pageof 28
The New England Journal of Medicine|January 11, 2018
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung CancerSanjay Popat
Annals of Palliative Medicine|April 6, 2015
Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?Sanjay Popat
Cancer|February 16, 2019
Hyperprogression with immunotherapy: Is it real?Sanjay Popat
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2019
Histologically Transformed SCLC From EGFR-Mutant NSCLC: Understanding the Wolf in Sheep's ClothingSanjay Popat
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Do Statins Improve Survival in Small-Cell Lung Cancer?Sanjay Popat
Thorax|April 12, 2013
What exactly are we doing to improve low lung cancer survival in the United Kingdom?Eric Lim, Sanjay Popat
Journal of Pediatric Surgery|November 18, 2005
Urethral polyp in neonate: a rare occurrenceAmit Sitapara, Sanjay Popat
Drugs|June 9, 2021
Immune Checkpoint Inhibition for Unresectable Malignant Pleural MesotheliomaWanyuan Cui, Sanjay Popat
Lancet (London, England)|July 9, 2023
Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligibleHazel O'Sullivan, Sanjay Popat
Therapeutic Advances in Medical Oncology|March 28, 2017
Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implicationsOscar Juan, Sanjay Popat
Pageof 28